DocMorris stock
DOCM.SWSIXDocMorris AG, HealthcareISIN CH0042615283
39Score 39 out of 100, Weak
Price and trend
86 / 100
Price history
+251% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 112% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 73).
The price is at its 52-week high. Largest decline in 9 years: 99% (February 2021 to March 2026).
Chart figures for advanced users
- SMA 50$16.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.79
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.80
- The lowest closing price of the last twelve months.
- Resistance$22.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- DocMorris AG belongs to the Medical (Distribution) industry (Switzerland) and, with a market value of $1.16B, is number 14 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.36B (up 10.6% year on year) and a loss of $161.95M.
- For fiscal 2026, analysts expect on average revenue of $1.54B (up 13.6%) and adjusted earnings per share of −$2.02.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 563 of 714 in Healthcare, median 53.
- Our model puts fair value at $15.66, with the price 44% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 180% since 2020.Capital allocation 18
- Loss-makingLoss of $151.77M over the last 12 months.Fundamentals 17
- Revenue shrinkingRevenue down 5.3% a year since 2020.Growth 33
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $11.19 and expensive above $26.10 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 6%. At 7% the fair value would be $12.75, at 5% it would be $19.93.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 11.3% on the twelve months before. Revenue has grown solidly since 2010, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 9%, operating −7%, net −12%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Mar 2027in 126 days
- Last reported
- 19 Aug 2026EPS reported −$1.33 (expected −$4.47)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.2% since 15 Oct 2026.
- Earnings per share
- −$2.02−0.9%
- Revenue
- $1.54B+1.3%
- Earnings per share
- −$0.97+5.2%
- Revenue
- $1.73B+2.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.1%2026 guidance raised: revenue growth of about 40% (before about 20%), EBITDA breakeven targeted in 2026, capital spending below CHF 30 million.
“That's the reason why we raised the soft guidance from around 20% growth to around 40% growth, which is already underlined with Q2 with over 40% quarterly growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 18 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at DocMorris
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- Asker Healthcare GroupASKER.ST $2.87B61
- Sopharma ADSPH.WA $1.9B57
- Redcare PharmacyRDC.DE $1.6B47
- UnipharUPR.IR $1.27B57
- Akso Health GroupAHG $1.15B36
- ArjoARJO-B.ST $927.89M58
- Neuca S.a.NEU.WA $788.51M59
- MediosILM1.DE $322.4M50
ETFs that hold DocMorris
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.85% | 0.68% | €5.31M |
| iShares Digitalisation UCITS ETF2B79 | 0.03% | 0.40% | €726.22M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2018)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.